Meningococcal Vaccines Market Size to Surpass $9.05 Billion, Globally, by 2032 at 10.4% CAGR: Coherent Market Insights [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
size is estimated to grow from US$ 4.53 Billion in 2025 and is forecast to reach a value of US$ 9.05 Billion by 2032 at a CAGR of 10.4% between 2025 and 2032. Request Sample Pages: https://www.coherentmarketinsights.com/insight/request-sample/3864 Global Meningococcal Vaccines Market Key Takeaways • The global meningococcal vaccines market size is anticipated to grow nearly 2X, expanding from USD 4.53 Bn in 2025 to USD 9.05 Bn by 2032, recording a CAGR of 10.4% throughout the forecast period. • Based on type, conjugate vaccines segment is expected to account for half of the revenue share in the global meningococcal vaccines market by 2025. This is due to advantages of conjugate vaccines, including long-lasting immunity and high avidity. • In terms of sales channel, public segment will likely account for a dominant 60.1% of the global meningococcal vaccines market share in 2025. • By age group, children and adults (2 years & above) segment is set to dominate the industry. C
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck's Keytruda [Seeking Alpha]Seeking Alpha
- KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery [Yahoo! FinaYahoo! Fina
- KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After SurgeryBusiness Wire
- Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? [Yahoo! Finance]Yahoo! Finance
- Here's How Many Shares of SCHD You'd Need for $1,000 in Yearly Dividends [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 12/4/25 - Form 8-K
- 12/3/25 - Form 424B5
- 12/2/25 - Form FWP
- MRK's page on the SEC website